EULAR 2024

IL-17 inhibition & new molecules

Difference in axial involvement in axSpA and axPsA

Subclinical PsA - where is the border?

Deeper B-cell depletion

Handling cardiovascular risks in RA

Tapering or even stopping TNF inhibitors in pts. with…

What advances the radiographic progression? IL-17A vs.…

Minimal spinal radiographic progression with…

Uterine inflammation in the pathogenesis in axSpA

Factors associated with spinal progression in axSpA

Avoiding overdiagnosis in axSpA

Treat-to-target in axSpA - a long way to go!

Neuroinflammation as possible cause of intestinal…

Sooner or later - when therapy with biologics?

Ruolo dell’infiammazione uterina nella patogenesi…

Treat-to-target bei der axSpA - a long way to go!

Früher oder später - wann Therapie mit Biologika?

Vermeidung von Überdiagnose bei axSpA

Minimale Röntgenprogression der Wirbelsäule unter…

Approccio treat-to-target per indurre una remissione…

Was treibt die Röntgenprogression an? IL-17A vs. TNF…

Subclinical PsA - where is the border?

Tyk2 inhibition in PsA - a new opportunity?

IL-17 inhibition & new molecules

A new injection for knee osteoarthritis

Sonelokimab, a new molecule for IL-17A & IL-17F…

Which treatment to prevent PsA from PsO?

The JAK family is growing. Another Tyk2 inhibitor: safe…

Small molecules with a better enthesitis efficacy - new…

Managing comorbidities in PsA

Cardiovascular outcome in PsA - TnF vs. IL-17…

The difficult cases in PsA

12-weeks results from the PRO-SPIRIT study

A lot of steroids always help - no matter the…

Treatment strategy in early PsA - TnF inhibitors or…

Post-hoc analysis on severe disease activity in PsA

Early prediction by FAPI-PET in PsA

Die JAK-Familie wächst. Ein weiterer Tyk2-Inhibitor:…

Rhumatisme psoriasique débutant : anti TNF ou pas?

Risque cardiovasculaire et rhumatisme psoriasique :…

Frühe Prädiktion durch FAPI-PET bei PsA

Quel traitement pour prévenir l’évolution du psoriasis…

Risultati a 12 settimane dello studio di Real World…

Sonelokimab, ein neues Molekül zur IL-17A- &…

Kleine Moleküle mit besserer Enthesitiswirkung - neue…

Viel Kortison hilft immer - Begleittherapie egal...

Handling cardiovascular risks in RA

Tapering or even stopping TNF inhibitors in pts. with…

Deeper B-cell depletion

New JAK inhibitor tested in a Phase III trial in China

Real-world data on safety of etanercept biosimilar

ARCTIC REWIND - Tapering not recommended in patients on…

Potential new treatment class in RA

Tapering of TNF Inhibitors in RA Patients with…

Debate on regulatory safety measures for JAKies based…

No new safety signals from the JAK-POT study

A model to predict progression from palindromic…

Good news in RA

Debate on therapeutic drug monitoring

Statins in RA - who benefits?

Anti-citrullinated protein antibody (ACPA) does not…

Un modelo para predecir la progresión del reumatismo…

Abatacept vs adalimumab en pacientes con AR doble…

ARCTIC REWIND – dosereduksjon og seponering anbefales…

Debatt om bruk av therapeutic drug monitoring (TDM,…

En ny JAK hemmer undersøkt i en fase III studie I Kina

Reducción y suspensión de los inhibidores del TNF en…

Keine neuen Safety-Signale aus der JAK-POT Studie

Debatt om regulatoriske krav om sikkerhet ved bruk av…

The role of rheumatoid factor from early to late

Holistic view on multidisciplinary care in rheumatology

How to treat Lupus: What's on the horizon?